HK StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

LEADS BIOLABS-B

65.000

-0.500-0.76%

Volume:256.80K

Turnover:16.83M

Market Cap:12.94B

PE:-32.37

High:66.550

Open:65.500

Low:64.200

Close:65.500

52wk High:83.600

52wk Low:44.720

Shares:199.00M

HK Float Shares:153.00M

Volume Ratio:0.66

T/O Rate:0.17%

Dividend:- -

Dividend Rate:- -

EPS(LYR):-2.008

ROE:--

ROA:--

PB:108.94

PE(LYR):-32.37

PS:- -

Loading ...

Overview Company News Filings

LEADS BIOLABS-B Shares Surge Over 8% in Morning Session on Inclusion in Key Index

LEADS BIOLABS-B (09887) Administers First Dose in Phase Ib/II Trial of Velesin™ for Recurrent or Metastatic Triple-Negative Breast Cancer

Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase Ib/II Trial of LBL-024 (Opamtistomig) for Recurrent or Metastatic TNBC

Bulletin Express

Nanjing Leads Biolabs startet Phase-Ib/II-Studie mit LBL-024 bei triple-negativem Brustkrebs

LEADS BIOLABS-B Surges Over 9% in Afternoon Trading as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation

LEADS BIOLABS-B (09887) Surges Nearly 6% Again as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation

LEADS BIOLABS-B (09887): LBL-034 (GPRC5D/CD3 Bispecific T-Cell Engager) Granted Fast Track Designation by US FDA

FDA Grants Fast Track Designation to Nanjing Leads Biolabs' LBL-034 for Relapsed/Refractory Multiple Myeloma

Nanjing Leads Biolabs Co Ltd - Lbl-034 Granted Fast Track Designation by FDA

THOMSON REUTERS

Hong Kong Stocks Movement | LEADS BIOLABS-B (09887) Surges Over 5% in Late Trading as Bispecific Antibody VELISIN Gains EU Orphan Drug Designation

LEADS BIOLABS-B (09887) Surges Over 5% as VELIXENT™ Receives Orphan Drug Designation from European Commission

LEADS BIOLABS-B (09887): Vilisin™ Granted Orphan Drug Designation (ODD) by European Commission for Treatment of Extrapulmonary Neuroendocrine Carcinoma

European Commission Grants Orphan Drug Designation to Nanjing Leads Biolabs’ LBL-024 for EP-NEC

Nanjing Leads Biolabs - Lbl-024 Receives Orphan Drug Designation by European Commission

THOMSON REUTERS

Plunge in Sector and Lock-up Expiry: How LEADS BIOLABS-B (09887) Attracts Incoming Northbound Capital?

Huafu Securities Initiates Coverage on LEADS BIOLABS-B (09887) with "Buy" Rating, Highlights Full Pipeline of Next-Generation IO and ADC Therapies

HK Stock Movement | LEADS BIOLABS-B (09887) Rises Over 4% as PD-L1/4-1BB Bispecific Antibody Gains FDA Fast Track Designation

Hong Kong Stock Announcement Highlights | BIODLINK-B Receives 99% Premium Cash Offer from WUXI XDC, Resumes Trading on January 15

LEADS BIOLABS-B (09887): Velixin™ (PD-L1/4-1BB Bispecific Antibody Opatisumimab, LBL-024) Granted FDA Fast Track Designation

FDA Grants Fast Track Designation to Nanjing Leads Biolabs' LBL-024 for EP-NEC

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/09887/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"09887","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","market":"HK","secType":"STK","nameCN":"LEADS BIOLABS-B","latestPrice":65,"timestamp":1771574918006,"preClose":65.5,"halted":0,"volume":256800,"delay":0,"changeRate":-0.007633587786259542,"floatShares":153000000,"shares":199000000,"eps":-2.008042,"marketStatus":"Not Yet Opened","change":-0.5,"latestTime":"02-20 16:08:38","open":65.5,"high":66.55,"low":64.2,"amount":16828025,"amplitude":0.035878,"askPrice":65,"askSize":600,"bidPrice":64.55,"bidSize":1500,"shortable":3,"etf":0,"ttmEps":-1.583,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1771810200000},"marketStatusCode":0,"adr":0,"listingDate":1753372800000,"exchange":"SEHK","adjPreClose":65.5,"openAndCloseTimeList":[[1771551000000,1771560000000],[1771563600000,1771574400000]],"volumeRatio":0.6561300280016972,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"09887\",,,,,undefined,":{"symbol":"09887","floatShares":153000000,"roa":"--","roe":"--","lyrEps":-2.008042,"volumeRatio":0.6561300280016972,"shares":199000000,"dividePrice":0,"high":66.55,"amplitude":0.035878,"preClose":65.5,"low":64.2,"week52Low":44.72,"pbRate":"108.94","week52High":83.6,"institutionHeld":0,"latestPrice":65,"committee":0.428571,"eps":-2.008042,"divideRate":0,"volume":256800,"delay":0,"ttmEps":-1.583,"open":65.5,"prevYearClose":51,"prevWeekClose":61.35,"prevMonthClose":66.85,"prevQuarterClose":51,"fiveDayClose":63.65,"twentyDayClose":52.5,"sixtyDayClose":53.1},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/09887\",params:#limit:5,,,undefined,":[{"date":"2025-08-29","symbol":"09887","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1756431000000,"name":null,"time":"","dateTimestamp":1756396800000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"09887\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"09887\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0.25,"buy":0.5,"hold":0.25,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.5,"analysts":4,"updateTime":1762185600000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/09887\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"09887","date":"2026-02-20","current":-41.061276,"percent":0.41844,"low":-50.052922,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"high":-30.202688,"avg":-38.248904,"sd":4.535707,"marketCap":12927967000},"quantilePoints":[{"date":"2025-07-25","current":-39.760016,"twenty":-39.760016,"median":-39.760016,"eighty":-39.760016,"marketCap":12652000240},{"date":"2025-08-01","current":-42.800562,"twenty":-46.836196,"median":-44.399434,"eighty":-42.800562,"marketCap":13535375000},{"date":"2025-08-08","current":-41.931377,"twenty":-45.734702,"median":-43.894587,"eighty":-42.800562,"marketCap":13293671875},{"date":"2025-08-15","current":-42.360797,"twenty":-44.683717,"median":-42.975881,"eighty":-41.70245,"marketCap":13409689375},{"date":"2025-08-22","current":-41.268557,"twenty":-45.0887,"median":-43.050098,"eighty":-41.70245,"marketCap":13022964375},{"date":"2025-08-29","current":-41.462871,"twenty":-44.683717,"median":-42.745269,"eighty":-41.268557,"marketCap":13146747980},{"date":"2025-09-05","current":-41.718992,"twenty":-44.115151,"median":-41.93996,"eighty":-40.603026,"marketCap":13087080440},{"date":"2025-09-12","current":-41.612383,"twenty":-43.894587,"median":-41.766832,"eighty":-40.253447,"marketCap":13077135850},{"date":"2025-09-19","current":-40.406926,"twenty":-43.894587,"median":-41.814673,"eighty":-40.270938,"marketCap":12689296840},{"date":"2025-09-26","current":-39.940552,"twenty":-43.592616,"median":-41.710721,"eighty":-39.940552,"marketCap":12510294220},{"date":"2025-10-03","current":-46.021818,"twenty":-44.124681,"median":-41.829747,"eighty":-40.190868,"marketCap":14449489270},{"date":"2025-10-10","current":-44.344385,"twenty":-44.480118,"median":-41.935668,"eighty":-40.263942,"marketCap":13902536820},{"date":"2025-10-17","current":-41.267963,"twenty":-44.480118,"median":-42.061577,"eighty":-40.352531,"marketCap":12927967000},{"date":"2025-10-24","current":-37.571928,"twenty":-44.331016,"median":-41.888099,"eighty":-40.263942,"marketCap":11774394560},{"date":"2025-10-31","current":-34.030535,"twenty":-44.258383,"median":-41.766832,"eighty":-39.846145,"marketCap":10680489660},{"date":"2025-11-07","current":-37.063837,"twenty":-44.143742,"median":-41.612383,"eighty":-39.421071,"marketCap":11625225710},{"date":"2025-11-14","current":-37.306884,"twenty":-44.026925,"median":-41.504614,"eighty":-38.171485,"marketCap":11734616200},{"date":"2025-11-21","current":-32.263354,"twenty":-43.773799,"median":-41.293984,"eighty":-37.626872,"marketCap":10143481800},{"date":"2025-11-28","current":-33.407237,"twenty":-43.416049,"median":-41.25873,"eighty":-37.278832,"marketCap":10541265400},{"date":"2025-12-05","current":-32.531883,"twenty":-43.110759,"median":-40.854935,"eighty":-36.232015,"marketCap":10282706060},{"date":"2025-12-12","current":-33.445348,"twenty":-43.033782,"median":-40.504976,"eighty":-34.804627,"marketCap":10590988350},{"date":"2025-12-19","current":-31.455565,"twenty":-42.962519,"median":-40.253447,"eighty":-33.697999,"marketCap":9984368360},{"date":"2025-12-24","current":-31.920084,"twenty":-42.892338,"median":-39.907071,"eighty":-33.445348,"marketCap":10163370980},{"date":"2026-01-02","current":-31.421623,"twenty":-42.818917,"median":-39.811672,"eighty":-33.24713,"marketCap":10044035900},{"date":"2026-01-09","current":-34.757237,"twenty":-42.712093,"median":-39.628079,"eighty":-33.303022,"marketCap":11137940800},{"date":"2026-01-16","current":-34.953981,"twenty":-42.570843,"median":-39.220132,"eighty":-33.387129,"marketCap":11237386700},{"date":"2026-01-23","current":-34.708884,"twenty":-42.534258,"median":-38.04671,"eighty":-33.234922,"marketCap":11147885390},{"date":"2026-01-30","current":-41.208386,"twenty":-42.402729,"median":-37.93488,"eighty":-33.285275,"marketCap":13295916830},{"date":"2026-02-06","current":-38.552413,"twenty":-42.362692,"median":-38.04671,"eighty":-33.303022,"marketCap":12470515860},{"date":"2026-02-13","current":-37.506904,"twenty":-42.335079,"median":-38.011119,"eighty":-33.387129,"marketCap":12202011930},{"date":"2026-02-20","current":-39.795685,"twenty":-42.275235,"median":-38.202679,"eighty":-33.413439,"marketCap":12927967000}],"updateTime":1771765944637},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"09887\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1167171731","title":"LEADS BIOLABS-B Shares Surge Over 8% in Morning Session on Inclusion in Key Index","url":"https://stock-news.laohu8.com/highlight/detail?id=1167171731","media":"Deep News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167171731?lang=en_us&edition=fundamental","pubTime":"2026-02-16 11:30","pubTimestamp":1771212623,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw its share price increase by 7.91% in the morning session, currently trading at HKD 66.20, with a turnover of HKD 28.44 million. On February 13, Hang Seng Indexes Company...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","09887","HSCI","BK1161","HK0000252160.HKD","HK0000252152.HKD"],"gpt_icon":0},{"id":"1110393588","title":"LEADS BIOLABS-B (09887) Administers First Dose in Phase Ib/II Trial of Velesin™ for Recurrent or Metastatic Triple-Negative Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=1110393588","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1110393588?lang=en_us&edition=fundamental","pubTime":"2026-02-10 16:48","pubTimestamp":1770713319,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that the first patient has been successfully dosed in an open-label, multicenter Phase Ib/II clinical study evaluating Velesin™ (Opatisumimab, LBL-024), a...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161","09887"],"gpt_icon":0},{"id":"1164574417","title":"Nanjing Leads Biolabs (9887) Announces First Patient Dosed in Phase Ib/II Trial of LBL-024 (Opamtistomig) for Recurrent or Metastatic TNBC","url":"https://stock-news.laohu8.com/highlight/detail?id=1164574417","media":"Bulletin Express","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164574417?lang=en_us&edition=fundamental","pubTime":"2026-02-10 16:45","pubTimestamp":1770713130,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. (Stock Code: 9887) reported that its bispecific antibody Opamtistomig (LBL-024), which targets both PD-L1 and 4-1BB, has successfully dosed the first patient in a...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887"],"gpt_icon":0},{"id":"2610612297","title":"Nanjing Leads Biolabs startet Phase-Ib/II-Studie mit LBL-024 bei triple-negativem Brustkrebs","url":"https://stock-news.laohu8.com/highlight/detail?id=2610612297","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2610612297?lang=en_us&edition=fundamental","pubTime":"2026-02-10 16:30","pubTimestamp":1770712244,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co. Ltd. hat bekannt gegeben, dass der erste Patient in einer Phase Ib/II-Studie mit Opamtistomig  zur Behandlung von rezidivierendem oder metastasierendem triple-negativem Brustkrebs behandelt wurde. Die multizentrische, offene Studie wird unter Leitung von Professor Ying Yongmei am Jiangsu Province Hospital und weiteren Kliniken in China durchgeführt. Ergebnisse der Studie wurden bislang noch nicht prsentiert.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on February 10, 2026, and is solely responsible for the information contained the","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260210:nNDL28H1Cl:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000252160.HKD","BK1161","09887","HK0000500386.USD"],"gpt_icon":0},{"id":"1151736923","title":"LEADS BIOLABS-B Surges Over 9% in Afternoon Trading as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1151736923","media":"Deep News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1151736923?lang=en_us&edition=fundamental","pubTime":"2026-01-30 14:22","pubTimestamp":1769754137,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) saw its share price climb 8.78% in the afternoon session, currently trading at HKD 65.65, with a turnover of HKD 52.8146 million. The company announced that on January 27th,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252160.HKD","BK1161","HK0000252152.HKD","09887"],"gpt_icon":0},{"id":"1133943748","title":"LEADS BIOLABS-B (09887) Surges Nearly 6% Again as TCE Bispecific Antibody LBL-034 Receives FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1133943748","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1133943748?lang=en_us&edition=fundamental","pubTime":"2026-01-29 11:09","pubTimestamp":1769656190,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose nearly 6% again. At the time of writing, the stock was up 4.63%, trading at HK$62.2, with a turnover of HK$11.4228 million. The company announced that LBL-034, its...","market":"other","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000500386.USD","HK0000252152.HKD","HK0000252160.HKD","VT","BK4585","BK4588","09887"],"gpt_icon":0},{"id":"1143084906","title":"LEADS BIOLABS-B (09887): LBL-034 (GPRC5D/CD3 Bispecific T-Cell Engager) Granted Fast Track Designation by US FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=1143084906","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1143084906?lang=en_us&edition=fundamental","pubTime":"2026-01-28 08:40","pubTimestamp":1769560813,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that on January 27, 2026, LBL-034 (a GPRC5D/CD3 bispecific antibody) was granted Fast Track Designation (FTD) by the U.S. Food and Drug Administration (FDA) for the treatment of relapsed/refractory multiple myeloma (RRMM).","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","BK1161","HK0000252152.HKD","09887","HK0000500386.USD"],"gpt_icon":0},{"id":"2606399754","title":"FDA Grants Fast Track Designation to Nanjing Leads Biolabs' LBL-034 for Relapsed/Refractory Multiple Myeloma","url":"https://stock-news.laohu8.com/highlight/detail?id=2606399754","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606399754?lang=en_us&edition=fundamental","pubTime":"2026-01-28 08:22","pubTimestamp":1769559757,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on January 28, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nNDL7XdZJg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD","BK1161","09887"],"gpt_icon":0},{"id":"2606754367","title":"Nanjing Leads Biolabs Co Ltd - Lbl-034 Granted Fast Track Designation by FDA","url":"https://stock-news.laohu8.com/highlight/detail?id=2606754367","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606754367?lang=en_us&edition=fundamental","pubTime":"2026-01-28 08:22","pubTimestamp":1769559752,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260128:nFWN3YS11G:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1161","09887","HK0000252160.HKD","HK0000500386.USD","HK0000252152.HKD"],"gpt_icon":0},{"id":"1184255807","title":"Hong Kong Stocks Movement | LEADS BIOLABS-B (09887) Surges Over 5% in Late Trading as Bispecific Antibody VELISIN Gains EU Orphan Drug Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1184255807","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1184255807?lang=en_us&edition=fundamental","pubTime":"2026-01-26 15:32","pubTimestamp":1769412740,"startTime":"0","endTime":"0","summary":"After a significant decline in the morning session, LEADS BIOLABS-B (09887) gradually turned positive, with its gains expanding to over 5% by the late trading period. At the time of writing, the...","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","FESXmain","HK0000500386.USD","HK0000252152.HKD","09887","FSXEmain","HK0000252160.HKD"],"gpt_icon":0},{"id":"1158679547","title":"LEADS BIOLABS-B (09887) Surges Over 5% as VELIXENT™ Receives Orphan Drug Designation from European Commission","url":"https://stock-news.laohu8.com/highlight/detail?id=1158679547","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1158679547?lang=en_us&edition=fundamental","pubTime":"2026-01-23 14:20","pubTimestamp":1769149221,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose more than 5%, with a gain of 4.94% at the time of writing to HK$55.2, and a turnover of HK$18.0035 million. On January 22, LEADS BIOLABS-B announced that on January 22,...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000500386.USD","HK0000252160.HKD","09887","BK1610","BK1161","02800","HK0000252152.HKD"],"gpt_icon":0},{"id":"1107142409","title":"LEADS BIOLABS-B (09887): Vilisin™ Granted Orphan Drug Designation (ODD) by European Commission for Treatment of Extrapulmonary Neuroendocrine Carcinoma","url":"https://stock-news.laohu8.com/highlight/detail?id=1107142409","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1107142409?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:10","pubTimestamp":1769087425,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that on January 22, 2026, the European Commission (EC) issued an executive decision dated January 9, 2026, granting Orphan Drug Designation (ODD) to the PD-L1/4-1BB...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","IE0009354923.USD","BK4183","HK0000252152.HKD","HK0000500386.USD","09887","ODD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2605999504","title":"European Commission Grants Orphan Drug Designation to Nanjing Leads Biolabs’ LBL-024 for EP-NEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2605999504","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605999504?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:59","pubTimestamp":1769086751,"startTime":"0","endTime":"0","summary":"Nanjing Leads Biolabs Co., Ltd. announced that the European Commission has granted Orphan Drug Designation  to LBL-024 , a PD-L1/4-1BB bispecific antibody, for the treatment of extrapulmonary neuroendocrine carcinoma . This follows a previous orphan designation for LBL-024 by the U.S. Food and Drug Administration  for the treatment of neuroendocrine carcinoma . The company also received approval from the National Medical Products Administration  in China to conduct a single-arm registrational trial and was granted Breakthrough Therapy Designation  by the NMPA for LBL-024 in late-line advanced EP-NEC.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Nanjing Leads Biolabs Co. Ltd. published the original content used to generate this news b","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL8VSCJv:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09887","BK1161","HK0000252152.HKD","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"2605499337","title":"Nanjing Leads Biolabs - Lbl-024 Receives Orphan Drug Designation by European Commission","url":"https://stock-news.laohu8.com/highlight/detail?id=2605499337","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605499337?lang=en_us&edition=fundamental","pubTime":"2026-01-22 20:58","pubTimestamp":1769086739,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nFWN3YN10M:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["HK0000500386.USD","HK0000252152.HKD","09887","HK0000252160.HKD","BK1161"],"gpt_icon":0},{"id":"1118629827","title":"Plunge in Sector and Lock-up Expiry: How LEADS BIOLABS-B (09887) Attracts Incoming Northbound Capital?","url":"https://stock-news.laohu8.com/highlight/detail?id=1118629827","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1118629827?lang=en_us&edition=fundamental","pubTime":"2026-01-22 16:53","pubTimestamp":1769072036,"startTime":"0","endTime":"0","summary":"On the evening of January 14, LEADS BIOLABS-B (09887) announced that its core investigational drug, the anti-PD-L1/4-1BB bispecific antibody VELIXIN® (LBL-024), was granted Fast Track designation by...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","09887","HK0000500386.USD","HK0000252160.HKD"],"gpt_icon":0},{"id":"1134047352","title":"Huafu Securities Initiates Coverage on LEADS BIOLABS-B (09887) with \"Buy\" Rating, Highlights Full Pipeline of Next-Generation IO and ADC Therapies","url":"https://stock-news.laohu8.com/highlight/detail?id=1134047352","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1134047352?lang=en_us&edition=fundamental","pubTime":"2026-01-22 16:51","pubTimestamp":1769071874,"startTime":"0","endTime":"0","summary":"Huafu Securities initiated coverage on LEADS BIOLABS-B (09887) with a \"Buy\" rating, projecting the company's revenues for 2025-2027 to be RMB 180 million, RMB 94 million, and RMB 10 million,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4231","HK0000500386.USD","161027","BK1161","BK4080","ADC","HK0000252152.HKD","09887","HK0000252160.HKD"],"gpt_icon":0},{"id":"1104680890","title":"HK Stock Movement | LEADS BIOLABS-B (09887) Rises Over 4% as PD-L1/4-1BB Bispecific Antibody Gains FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1104680890","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104680890?lang=en_us&edition=fundamental","pubTime":"2026-01-15 10:06","pubTimestamp":1768442788,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) rose more than 4%. As of the time of writing, the stock was up 4.26% to HK$56.3, with a turnover of HK$3.0003 million. On the evening of January 14, LEADS BIOLABS announced...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","LU1169589451.USD","09887","HK0000252160.HKD","PD","HK0000500386.USD","BK4023","HK0000252152.HKD","LU1169590202.USD"],"gpt_icon":0},{"id":"1137624204","title":"Hong Kong Stock Announcement Highlights | BIODLINK-B Receives 99% Premium Cash Offer from WUXI XDC, Resumes Trading on January 15","url":"https://stock-news.laohu8.com/highlight/detail?id=1137624204","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1137624204?lang=en_us&edition=fundamental","pubTime":"2026-01-14 23:14","pubTimestamp":1768403671,"startTime":"0","endTime":"0","summary":"Major Developments: Longqi Technology (09611) will conduct its IPO from January 14 to January 19, planning a global offering of 52.2591 million H shares. Hutchmed (00013) announced that the results...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","LU1522347837.USD","BK1191","HK0000500386.USD","BK1141","HK0000252152.HKD","BK1560","BK1516","LU1720050803.USD","00998","LU1497733557.USD","LU1634259391.SGD","LU0264606111.USD","09887","06887","LU1794554557.SGD","BK1574","LU0456827905.SGD","LU0210526637.USD","BK1521","BK1161","06030","BK1147","LU0572940350.SGD","02268","BK1231","LU1497733631.SGD","01875","LU1497734951.SGD","BK1564","LU1634259557.SGD","LU0572939691.SGD","LU0051755006.USD","LU2488822045.USD","SG9999014674.SGD"],"gpt_icon":0},{"id":"1195781349","title":"LEADS BIOLABS-B (09887): Velixin™ (PD-L1/4-1BB Bispecific Antibody Opatisumimab, LBL-024) Granted FDA Fast Track Designation","url":"https://stock-news.laohu8.com/highlight/detail?id=1195781349","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1195781349?lang=en_us&edition=fundamental","pubTime":"2026-01-14 23:00","pubTimestamp":1768402837,"startTime":"0","endTime":"0","summary":"LEADS BIOLABS-B (09887) announced that on January 14, 2026, its PD-L1/4-1BB bispecific antibody, Velixin™ (Opatisumimab, LBL-024), was granted Fast Track Designation by the U.S. Food and Drug...","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","HK0000252152.HKD","PD","09887","LU1169589451.USD","LU1169590202.USD","HK0000500386.USD","HK0000252160.HKD","BK4023"],"gpt_icon":0},{"id":"2603612412","title":"FDA Grants Fast Track Designation to Nanjing Leads Biolabs' LBL-024 for EP-NEC","url":"https://stock-news.laohu8.com/highlight/detail?id=2603612412","media":"Reuters","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603612412?lang=en_us&edition=fundamental","pubTime":"2026-01-14 22:45","pubTimestamp":1768401936,"startTime":"0","endTime":"0","summary":"FDA Grants Fast Track Designation to Nanjing Leads Biolabs' LBL-024 for EP-NEC               Nanjing Leads Biolabs Co. Ltd. announced that its investigational drug LBL-024 (Opamtistomig), a...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260114:nNDLp89RT:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["HK0000252160.HKD","09887","HK0000500386.USD","HK0000252152.HKD","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":5,"pageCount":1,"totalSize":86,"code":"91000000","status":"200"}]}}